Document is current

Article History

Received: 16 December 2024

Accepted: 11 April 2025

First Online: 23 April 2025

Declarations

:

: This study was approved by the Ethics Committee of the University of Bari Medical School (Study No. 7411, Protocol No. 0073322, approved on 26/08/2022 and Study No. 1879, Protocol No. 808 approved on 02/10/2024). All procedures involving human participants were conducted following the ethical standards outlined in the Declaration of Helsinki. Written informed consent was obtained from all enrolled patients before they participated in the study.

: All participants provided written informed consent for the publication of anonymized data derived from this study.

: A.G.S. has received speaker honorariums from Sanofi, Amgen, and AstraZeneca. He has also participated on advisory boards for Pfizer and Menarini. He received travel support for educational purposes from Janssen Cilag. C.B. has served as a speaker or consultant for Amgen, Janssen Cilag, Pfizer, Sanofi Aventis, Takeda, GSK, Oncopeptides. A.V. received speaker honorariums from Pfizer, Sanofi, Bristol Myers Squibb, Takeda, Janssen Cilag, AstraZeneca, Menarini, and Amgen. R.R. has served as a speaker or consultant for Amgen, BMS-Celgene, CSL Behring, Janssen Cilag, Octapharma, Pfizer, Sanofi, Takeda. These potential conflicts of interest do not imply bias or influence on the authors’ opinions or actions. The authors are aware of the importance of transparency in the scientific field and are committed to defending their integrity and the trust in them within the scientific community.